SCHEMBL6209489

SCHEMBL6209489

Cn1ccc2cc(Nc3nccc(NCc4ccccn4)n3)ccc21

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 2/20 0.66
PTK2B Q14289 2/20 0.66
KCNH2 Q12809 2/20 0.46
SYK P43405 3/20 0.44
GRM4 Q14833 1/20 0.44
KDM4E B2RXH2 5/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
TP53 P04637 3/20 0.43
ALDH1A1 P00352 2/20 0.43
HTT P42858 2/20 0.43
MAPT P10636 2/20 0.43
PKM P14618 1/20 0.43
ALOX15 P16050 1/20 0.43
KDR P35968 2/20 0.43
GAA P10253 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
JAK2 O60674 2/20 0.41
FLT3 P36888 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6211452 0.82 PTK2 (0.75) PTK2PTK2BGRM4FGFR1
SCHEMBL6216143 0.82 PTK2 (0.75) PTK2PTK2BGRM4KDM4ENPC1
SCHEMBL6211140 0.80 PTK2 (1.00) PTK2PTK2BFLT3IGF1R
SCHEMBL6210739 0.77 SYK (0.50) PTK2PTK2BKCNH2SYKKDM4E
SCHEMBL6260423 0.77 EGFR (0.51) PTK2PTK2BKCNH2SYKKDM4E
SCHEMBL6259622 0.76 PTK2 (0.67) PTK2PTK2BSYKKDRJAK2
SCHEMBL6212366 0.75 PTK2 (0.63) PTK2PTK2BGRM4KDM4ETP53
SCHEMBL6258964 0.74 SYK (0.47) PTK2PTK2BKCNH2SYKKDM4E
SCHEMBL6210596 0.74 KCNH2 (0.47) PTK2PTK2BKCNH2SYKKDM4E
Ammonia Solution, Strong SCHEMBL6833527 0.74 PTK2 (0.57) PTK2PTK2BSYKGRM4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP claimed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US claimed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO claimed
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP disclosed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US disclosed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220177-A1 Compound for the treatment of abnormal cell growth CCNA1, CCNB1, CCNT1 PTK2 3004/4885PTK2B 1941/4885KCNH2 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.